ライフサイエンスコーパス: diuretic agent

1 least 3 antihypertensive drugs, including a diuretic agent.

2 ts presenting with AHF requiring intravenous diuretic agents.

3 or those patients who do not respond to loop diuretic agents.

4 ty, electrolyte content, and the presence of diuretic agents.

5 d patients with AHF treated with intravenous diuretic agents.

6 class, diastolic blood pressure, and use of diuretic agents.

7 We compared HFrEF patients treated with diuretic agents alone to three treatment arms: 1) ACEI t

8 ive cardiomyopathies are limited to digoxin, diuretic agents and angiotensin-converting enzyme inhibi

9 t impair this mechanism (e.g., thiazide-type diuretic agents and mineralocorticoid receptor antagonis

10 tween neuroblastoma and maternal exposure to diuretic agents, antiinfective agents, estrogens, proges

11 Thiazide and thiazide-like diuretic agents are being increasingly used at lower dos

12 Thiazide diuretic agents are widely used for prevention of the re

13 acting agents (e.g., acetazolamide and loop diuretic agents) are preferred.

14 kely to be treated with high doses of a loop diuretic agent as an outpatient (all p < 0.001).

15 CCBs (hazard ratio 1.49 considering thiazide diuretic agents as a comparator; 95% CI, 1.04-2.14) but

16 Association class at randomization, and loop diuretic agent before hospitalization.

17 in, or enrichment of intestinal Roseburia by diuretic agents combined with beta-blockers.

18 Diuretic agents continue to be used in this setting desp

19 Simultaneous infusion of the diuretic agent furosemide prevented the AVP-induced decr

20 failure and to have received an intravenous diuretic agent in an outpatient setting in the previous

21 elf impairs delivery of effective amounts of diuretic agent into the urine, the site of action.

22 decongest patients as much as possible with diuretic agents (loop diuretic agents, thiazides, acetaz

23 full-dose antihypertensive drugs including a diuretic agent or >/=4 drugs): control (ABP <125/75 mm H

24 a lower hemoglobin (P = 0.025), require >=2 diuretic agents pretransplant (P = 0.051), or be transpl

25 effects on HF symptoms, renal function, and diuretic agent requirement over time.

26 dding a second-line diuretic agent to a loop diuretic agent, should be reserved for those patients wh

27 as been demonstrated for the use of digoxin, diuretic agents, sodium-glucose cotransporter 2 inhibito

28 In contrast, compared with diuretic agents, some data suggest that adjustment of ul

29 ephron segments with low water permeability, diuretic agents that impair this mechanism (e.g., thiazi

30 s and congestion can be controlled with loop diuretic agents, the main focus should be rapid guidelin

31 tion rate, and fewer new initiations of loop diuretic agent therapy.

32 again discontinued all antihypertensive and diuretic agents; they were progressed to a captopril dos

33 much as possible with diuretic agents (loop diuretic agents, thiazides, acetazolamide) or mechanical

34 anced decongestion, ie, adding a second-line diuretic agent to a loop diuretic agent, should be reser

35 tion of dietary sodium intake and the use of diuretic agents to enhance urinary sodium excretion.

36 se of antihypertensive medication other than diuretic agents was associated with decreased gout risk

37 ronolactone, but administration of all other diuretic agents was discontinued.

38 Antihypertensive and diuretic agents were discontinued 10 days before.

39 h subsequent worsening requiring intravenous diuretic agents, were assessed.

40 The former is caused by diuretic agents, which enhance sodium excretion, often w

41 ated with stable doses of ACE inhibitors and diuretic agents, with or without concurrent digitalis an